Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.

[1]  Y. Nishiwaki,et al.  Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. , 2008, The Lancet. Oncology.

[2]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[3]  Shigemi Matsumoto,et al.  The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric Cancer , 2008, Oncology.

[4]  G. Secreto,et al.  Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia. , 2007, In vivo.

[5]  K. Kiura,et al.  Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  M. Gore,et al.  Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Claudio Franceschi,et al.  The Genetics of Human Longevity , 2006, Annals of the New York Academy of Sciences.

[8]  N. Marcussen,et al.  Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial , 2006, British Journal of Cancer.

[9]  M. ChB.,et al.  Neutrophil‐lymphocyte ratio as a prognostic factor in colorectal cancer , 2005, Journal of surgical oncology.

[10]  J. Gehl,et al.  Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model , 2005, British Journal of Cancer.

[11]  Eileen M. Crimmins,et al.  Inflammatory Exposure and Historical Changes in Human Life-Spans , 2004, Science.

[12]  W. Sauerbrei,et al.  Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint , 2004, Statistics in medicine.

[13]  H. Bruunsgaard,et al.  Inflammatory mediators in the elderly , 2004, Experimental Gerontology.

[14]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Ferrigno,et al.  Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. , 2003, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[16]  P. Royston,et al.  Metastatic renal carcinoma comprehensive prognostic system , 2003, British Journal of Cancer.

[17]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[19]  Y. Fukushima,et al.  Growth stimulation of non-small cell lung cancer xenografts by granulocyte-macrophage colony-stimulating factor (GM-CSF). , 1998, European journal of cancer.

[20]  G. Chatta,et al.  Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. , 1996, Blood.

[21]  M. Furihata,et al.  Establishment of a Clonal Cell Line Producing Granulocyte Colony‐Stimulating Factor and Parathyroid Hormone‐Related Protein from a Lung Cancer Patient with Leukocytosis and Hypercalcemia , 1996, Japanese journal of cancer research : Gann.

[22]  T. Nishi,et al.  Autocrine Growth of Transitional Cell Carcinoma of the Bladder Induced by Granulocyte-Colony Stimulating Factor 1 , 2006 .

[23]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[25]  T. Uchida,et al.  Kinetics of rG-CSF-induced neutrophilia in mice. , 1992, Experimental hematology.

[26]  Thomas,et al.  In vivo hematologic effects of recombinant human macrophage colony-stimulating factor. , 1990, Blood.

[27]  A Howell,et al.  The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Demetri,et al.  Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. , 1989, Blood.

[29]  W. Piacibello,et al.  Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. , 1989, The Journal of clinical investigation.

[30]  H. Shau,et al.  Suppression of lymphokine-activated killer induction by neutrophils. , 1988, Journal of immunology.

[31]  T. Ulich,et al.  Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. , 1987, Journal of immunology.

[32]  R. Clark,et al.  Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. , 1987, Journal of immunology.

[33]  M. Lilly,et al.  Production of granulocyte colony-stimulating factor by a human melanoma cell line. , 1987, Experimental hematology.

[34]  P. Nowell,et al.  Molecular cloning and characterization of a cDNA for human granulocyte colony-stimulating factor (G-CSF) from a glioblastoma multiforme cell line and localization of the G-CSF gene to chromosome band 17q21. , 1987, Oncogene research.

[35]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[36]  L. Klassen,et al.  Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. , 1985, Journal of immunology.

[37]  T. Ulich,et al.  In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. , 1989, Blood.

[38]  T. Ulich,et al.  The hematologic effects of chronic administration of the monokines tumor necrosis factor, interleukin-1, and granulocyte-colony stimulating factor on bone marrow and circulation. , 1989, The American journal of pathology.

[39]  S. Nagata,et al.  Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor , 1986, Nature.

[40]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.